Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | CDK1 | P06493 | 9/20 | 1.00 |
| ▸ | SRC | P12931 | 7/20 | 1.00 |
| ▸ | ABL1 | P00519 | 13/20 | 0.89 |
| ▸ | PRKCA | P17252 | 9/20 | 0.89 |
| ▸ | ABL2 | P42684 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.52 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.50 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406521 | 0.94 | EGFR (0.89) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL6185419 | 0.94 | EGFR (1.00) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8580911 | 0.93 | EGFR (0.88) | EGFRCDK1SRCABL1PRKCA | |
| Hydrochloric Acid SCHEMBL8653420 | 0.93 | EGFR (0.88) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8579561 | 0.92 | EGFR (0.86) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8117285 | 0.91 | EGFR (0.85) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8579811 | 0.91 | EGFR (0.85) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8123060 | 0.90 | EGFR (1.00) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8578312 | 0.90 | EGFR (0.81) | EGFRCDK1SRCABL1PRKCA | |
| SCHEMBL8579562 | 0.90 | EGFR (0.81) | EGFRCDK1SRCABL1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819129-B1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2000-08-02 | — | — | EP | claimed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | claimed |
| EP-0819129-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031510-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | claimed |
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-0819129-B1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2000-08-02 | — | — | EP | disclosed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | disclosed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| EP-0819129-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031510-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | disclosed |